We also note that the device associated with this procedure (AGENT TM Paclitaxel-Coated Balloon Catheter) received device pass-through status effective January 1, 2025 (89 FR 91434 through 91439)
These searches reflect one thing: People want convenience
While the preclinical safety profile appears favorable (few adverse effects reported in animal studies), this does not guarantee the same in humans, especially with prolonged use
Further structural comparison of our FAT-1907 structure to that of the FAT-LD2 complex shows that, overall, the arrangement of the FAT domain was mostly conserved (root-mean-square deviation: 0.603)
Patients do not typically describe dramatic new growth, but they consistently describe hair that feels different, denser, stronger, with improved texture and reduced breakage
Burkett, J